



## OPEN Sublingual microcirculatory assessment on admission independently predicts the outcome of old intensive care patients suffering from shock

Raphael Romano Bruno<sup>1</sup>, Mara Schemmelmann<sup>1</sup>, Johanna Hornemann<sup>1</sup>, Helene Mathilde Emilie Moecke<sup>1</sup>, Filiz Demirtas<sup>1</sup>, Lina Palici<sup>1</sup>, Radost Marinova<sup>1</sup>, Dominika Kanschik<sup>1</sup>, Stephan Binnebösel<sup>1</sup>, Armin Spomer<sup>1</sup>, Bertrand Guidet<sup>2,3</sup>, Susannah Leaver<sup>4</sup>, Hans Flaatten<sup>5</sup>, Wojciech Szczeklik<sup>6</sup>, Maciej Mikiewicz<sup>6</sup>, Dylan W. De Lange<sup>7</sup>, Stanislas Quenard<sup>2,3</sup>, Michael Beil<sup>8</sup>, Malte Kelm<sup>1,9</sup> & Christian Jung<sup>1,9,10</sup>✉

Shock is a life-threatening condition. This study evaluated if sublingual microcirculatory perfusion on admission is associated with 30-day mortality in older intensive care unit (ICU) shock patients. This trial prospectively recruited ICU patients ( $\geq 80$  years old) with arterial lactate above 2 mmol/L, requiring vasopressors despite adequate fluid resuscitation, regardless of shock cause. All patients received sequential sublingual measurements on ICU admission ( $\pm 4$  h) and 24 ( $\pm 4$ ) hours later. The primary endpoint was 30-day mortality. From September 4th, 2022, to May 30th, 2023, 271 patients were screened, and 44 included. Patients were categorized based on the median percentage of perfused small vessels (SPPV) into those with impaired and sustained microcirculation. 71% of videos were of good or acceptable quality without safety issues. Patients with impaired microcirculation had significantly shorter ICU and hospital stays ( $p = 0.015$  and  $p = 0.019$ ) and higher 30-day mortality (90.0% vs. 62.5%,  $p = 0.036$ ). Cox regression confirmed the independent association of impaired microcirculation with 30-day mortality (adjusted hazard ratio 3.245 (95% CI 1.178 to 8.943,  $p = 0.023$ ). Measuring sublingual microcirculation in critically ill older patients with shock on ICU admission is safe, feasible, and provides independent prognostic information about outcomes.

Trial registration NCT04169204.

**Keywords** Microcirculation, Shock, Intensive care, Sidestream-dark field video-microscope, Intravital microscopy

Shock is a life-threatening condition characterised by an imbalance between tissue oxygen supply and demand<sup>1</sup>. Microcirculation, comprising vessels  $< 100 \mu\text{m}$  in diameter, plays a critical role in tissue perfusion<sup>2</sup>

<sup>1</sup>Medical Faculty, Department of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. <sup>2</sup>Equipe: épidémiologie hospitalière qualité et organisation des soins, Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR\_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris 75012, France. <sup>3</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris 75012, France. <sup>4</sup>General Intensive care, St George's University Hospitals NHS Foundation trust, London, UK. <sup>5</sup>Department of Clinical Medicine, Department of Anaesthesia and Intensive Care, University of Bergen, Haukeland University Hospital, Bergen, Norway. <sup>6</sup>Centre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland. <sup>7</sup>Department of Intensive Care Medicine, University Medical Center, University Utrecht, Utrecht, the Netherlands. <sup>8</sup>General and Medical Intensive Care Units, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. <sup>9</sup>CARID (Cardiovascular Research Institute Duesseldorf), Duesseldorf, Germany. <sup>10</sup>Division of Cardiology, Pulmonology, and Vascular Medicine, University Duesseldorf, Moorenstraße 5, 40225 Duesseldorf, Germany. ✉email: christian.jung@med.uni-duesseldorf.de

and homeostasis<sup>3</sup>, making it a central aspect of clinical practice<sup>4</sup>. Despite efforts in intensive care medicine to optimise systemic blood pressure to improve microcirculation, recent studies have shown neutral results<sup>2,5</sup>. Several indirect methods have been proposed to assess microcirculation, such as serum lactate [6], capillary refill time<sup>6</sup>, or the mottling score<sup>7</sup>, which could serve as appropriate resuscitation targets in shock scenarios<sup>8</sup>. Among patients suffering from shock, critically ill very old intensive care patients (VIPs) are generally high-risk patients<sup>9</sup>. Recent VIP studies found a 30-day-mortality between 38.8% and 43%<sup>10–12</sup>. VIPs represent one of the fastest growing subgroups within the intensive care unit (ICU) population<sup>13</sup>. In the European Union, approximately 24.4 million people are expected to be over 85 years of age by 2040. Globally, the proportion of patients aged over 60 years is expected to increase from approximately 12% in 2013 to 21% by 2050<sup>14</sup>. This demographic shift has already had an impact on intensive care unit (ICU) admission rates of VIPs in recent years<sup>15</sup>. Especially in these patients, technologies that might optimize the outcome prediction and treatment optimization in shock, are urgently needed. For this purpose, image-based direct visualisation techniques, including sidestream darkfield-cameras (SDF), have also been developed using intravital microscopy<sup>16</sup>. Numerous studies have shown a correlation between the severity of microcirculatory disturbances and the outcomes in critically ill patients<sup>17–20</sup>. Hand-held devices such as SDF cameras offer a standardised, rapid, and non-invasive assessment of the microcirculation at the sublingual mucosa, the feasibility of which has been positively evaluated even in elderly dehydrated patients<sup>21</sup>. The results may correlate with microcirculation in relevant territories such as the intestinal mucosa, thus serving as a suitable surrogate parameter for whole-body microcirculation<sup>2,22,23</sup>. Automated analysis of video sequences by the AVA 4.3 C software provides an objective evaluation of microcirculatory variables, minimising dependence on subjective visual interpretation<sup>24</sup>. Recently, a large multicentre randomised controlled trial (DAMIS) found no survival benefit from repeated SDF-based treatment optimisation in critically ill shock patients<sup>25–28</sup>. The current study aims at increasing knowledge and create potential cut-offs in old ICU patients for potential use in future clinical trials. Therefore, we conducted this prospective observational study for distinct microcirculatory phenotyping in a particularly vulnerable subgroup of old patients suffering from shock. In sum, this study aimed to test the hypothesis that sublingual microcirculatory assessment on ICU admission predicts 30-day mortality in vulnerable patients aged 80 years or older.

## Methods

### Study design

The Ethics Committee of the University of Duesseldorf, Germany, provided the principal ethical permission. All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent from patients or their surrogates was mandatory. The trial (Very old intensive care patients—perfusion, VIPPER) was registered on clinicaltrials.gov (NCT04169204) on November 14th, 2019.

### Patient selection

To be included, patients had to be 80 years old or older suffering from shock on intensive care unit (ICU) admission. For this study shock was characterised as the requirement for vasopressors despite adequate fluid resuscitation and an elevated lactate level ( $> 2$  mmol/L) indicating of hypotension and hypoperfusion<sup>29</sup>. Determination of adequate fluid replacement was left to the discretion of the attending intensivist, as described previously<sup>25</sup>. Inclusion in the study necessitated the provision of a signed informed consent. When patients could not provide consent, a provisional informed consent form was signed by a medical witness or legal guardian. Exclusion criteria encompassed inaccessibility of the sublingual mucosa, inability to obtain measurements during the inclusion period due to ongoing examinations/treatments/terminal patient status, uncooperative/weakly sedated patients, or infectious conditions that presented a high probability of respiratory viremia, including but not limited to Covid-19 and Influenza. This refinement was necessitated by the stringent guidelines and local standard operating procedures implemented during the initial phase of the Covid-19 pandemic, which mandated strict limitations on non-essential airway interventions and diagnostics to safeguard patient and staff safety and comply with urgent public health directives. Consequently, patients with these infectious conditions were excluded from the VIPPER study to ensure adherence to these critical operational protocols and to maintain the integrity and safety of the study for all participants.

### Sublingual measurement

The assessment of microcirculation in the sublingual region was conducted using the MicroScan USB3 (MS-U) sidestream darkfield (SDF) video-microscope, both upon admission to the Intensive Care Unit (ICU) (within a maximum time frame of 4 h) and 24 h later ( $\pm 4$  h) following ICU admission. After the measurement, the four highest-quality video sequences, captured at distinct locations on the sublingual mucosa, were evaluated using the AVA 4.3 C algorithm. The resultant variables from these sequences were averaged for analysis<sup>24</sup>. Investigators did not manually calculate any variables. A proof-of-concept study was undertaken to establish the feasibility of this particular method for microcirculation measurement<sup>30</sup>. Subsequently, the quality of the videos was evaluated by trained personnel in a blinded manner, employing the microcirculation-imaging-quality-score (MIQS)<sup>31</sup>.

Furthermore, additional patient-related information was gathered in both cohorts, encompassing macrocirculatory variables such as blood pressure, supplementary microcirculatory parameters such as mottling score or capillary refill time, blood gas analysis values, and administered medications. The microcirculatory assessment was conducted in a blinded manner, independent of the treatment team. A single investigator performed both consecutive measurements. The De Backer Density and the Number of Crossings denote the count of detectable vessels, while the perfused De Backer Density and the Perfused Number of Crossings represent vessels exhibiting visible microcirculatory flow. The Percentage of Perfused Vessels is calculated as the

proportion of perfused vessels relative to the total number of all vessels. Small vessels (capillaries) are defined as those smaller than 20  $\mu\text{m}$ <sup>32</sup>.

Patients were retrospectively divided into two risk categories according to their sPPV on admission. The cut-offs were chosen *a posteriori* with an sPPV equal to or greater than 83% as “preserved” and values less than 83% as “impaired” microcirculation based on the included median value of the cohort. There is no commonly accepted definition for cut-offs. Other classifications use 95% as “healthy,” 81–94% as “unhealthy,” and values less than 80% as “dangerous,” depending on the literature from clinical studies<sup>33,34</sup> and healthy volunteers<sup>35–37</sup>. Other studies consider a PPV < 90% abnormal<sup>16,38</sup>.

### Definition of limitation of life-sustaining therapy

If a patient had a medical indication for specific intensive care measures (typically including intubation and ventilation, cardiopulmonary resuscitation, catecholamine therapy, or haemodialysis), but these interventions were not administered due to the patient’s explicit will, ethical considerations, or in the context of a palliative care situation, such instances were categorised as “withheld therapy.” On the other hand, if any of these measures were initiated but the patient subsequently expressed a desire to terminate the therapy during the course of intensive care, such cases were defined as “withdrawn therapy”<sup>25,39</sup>.

### Cause of shock and comorbidities

Determining the cause of shock was primarily based on aetiology rather than underlying physiology. Specifically, patients with a primary infectious aetiology were classified as experiencing “septic shock” following the Sepsis-3 criteria<sup>29</sup>, and in case of a primary cardiac aetiology (e.g., acute myocardial infarction or acute heart failure) as “cardiogenic shock.” Comorbidities were obtained from health records, and their presence was documented in a binary manner. If a particular condition was identified, irrespective of its severity or aetiology, it was recorded as “present”; otherwise, it was noted as “not present.”


### Statistical analysis

The primary outcome was 30-day mortality. Continuous data points were expressed as median  $\pm$  interquartile range. Statistical significance in differences between independent groups was calculated using the Mann-Whitney U-test or student’s t-test depending on the data distribution. Categorical data are expressed as numbers (percentages). The Chi<sup>2</sup> test was applied to test differences between groups for their statistical significance. Univariate and multivariate Cox regression analysis calculated hazard ratios with 95% CI. Multivariate Cox regression was chosen for adjusting patient age, gender and the Sequential Organ Failure Assessment (SOFA) score in recognition of its suitability for analysing time-to-event data, such as 30-day mortality. Patient age served as a demographic variable. Including the SOFA score allowed for considering baseline organ dysfunction severity, enhancing the precision of assessing the impact of other factors on time to the event of interest based on the current evidence<sup>25,40–42</sup>. An additional Cox proportional hazards regression analysis was conducted to evaluate the impact of sPPV on 30-day mortality. Kaplan–Meier curves were depicted to compare the cumulative incidence of mortality after 30 days. The coefficient of variation (cv%) was calculated by dividing the standard deviation by the mean and multiplying the result by 100 to express it as a percentage. Missing values were defined as “missing values,” and a complete-cases analysis was conducted. Unless otherwise stated, there were no missing values for the variables examined in the statistical analysis. Baseline and other variables that are not outcomes were not tested for statistically significant differences. For lactate kinetics, Delta6h and Delta24h were calculated as described previously<sup>40,43</sup>. All tests were two-sided, and a p-value of < 0.05 was considered statistically significant. Analyses were conducted using IBM SPSS Statistics (Version 28). Python 3.12.4 with Visual Studio Code (Version 1.92.0, Microsoft, Redmond, Washington, USA) was used with the lifelines library to compute and display Kaplan–Meier curves, employing the KaplanMeierFitter function for survival analysis and matplotlib for visualizing the results, including formatting the y-axis as percentage values using PercentFormatter. was used for the depiction of Kaplan–Meier comparison.

## Results

### Patients’ baseline characteristics

From September 4th, 2022, to May 30th, 2023, 63 patients were screened, with 47 meeting the inclusion criteria for shock. Three patients had to be excluded afterward due to missing a suitable SDF measurement on admission (Fig. 1). Thus, 44 patients were analysed and divided according to the median sPPV: 24 patients (55%) demonstrated a preserved, and 20 patients (46%) had an impaired microcirculation. Table 1 provides a detailed comparison between patients with preserved and impaired microcirculation, including various demographic and clinical parameters. A significant difference in gender distribution was observed, with 70% males in the impaired microcirculation group compared to 29% in the preserved microcirculation group ( $p = 0.007$ ). There were no significant differences in age between the two groups, with a mean age of 85 years ( $\pm 1$ ) for preserved microcirculation and 84 years ( $\pm 1$ ) for impaired microcirculation ( $p = 0.476$ ). Body temperature, respiratory rate, mean arterial pressure, systolic and diastolic arterial pressures, heart rate, SOFA score on admission, body mass index, weight, and length did not differ significantly between the groups. The cause of shock, categorised as sepsis, cardiogenic, neurological, or haemorrhagic, did not exhibit a significant difference ( $p = 0.594$ ). Comorbidities, including heart failure, chronic kidney disease, malignancy, diabetes mellitus, chronic obstructive pulmonary disease, liver cirrhosis, smoking history, and arterial hypertension, also did not show any significant differences between the two groups.



**Fig. 1.** Consort diagram.

### Video quality

A total of 354 videos underwent retrospective quality control conducted by blinded investigators. Approximately 70% of the videos were deemed good or acceptable based on the quality assessment. The analysis of the most frequent error points, considering all Medical Image Quality Standard (MIQS) criteria, revealed that “stability” accounted for 22%, while “pressure” constituted 33% of the identified issues. The primary reasons for videos being categorised as “not acceptable” included pressure (39%; CV% 247%), stability (24%; CV% 323%), content (23%; CV% 329%), and focus (15%; CV% 420%).

### Microcirculation on ICU admission

The cox-regression of all patients revealed that sPPV was associated significantly with 30-day survival (HR 0.976 (95% CI 0.958–0.993,  $p=0.006$ )). This indicates that for percent decrease in sPPV, the risk of 30-day survival decreases by approximately 2.4%. The results presented in Table 2 delineate several haemodynamic and microcirculatory parameters among patients with impaired and preserved microcirculation. Capillary refill time and lactate levels on admission demonstrated no significant differences between the two groups ( $p>0.05$ ). Regarding Sidestream Dark Field (SDF) measurements at baseline, the number of crossings, De-Backer density, number of crossings (small vessels), and De-Backer density (small vessels) did not exhibit statistically significant differences between the groups ( $p>0.05$ ). However, the perfused number of crossings, perfused De-Backer density, percentage of perfused vessels, and percentage of perfused small vessels were significantly higher in the preserved microcirculation group compared to the impaired microcirculation group ( $p<0.05$  for all variables). Specifically, the percentage of perfused vessels was  $92.9\pm 4.2\%$  in the preserved microcirculation group, significantly higher than the  $87.4\pm 4.2\%$  observed in the impaired microcirculation group ( $p=0.014$ ). Similarly, the percentage of perfused small vessels was markedly higher in the preserved microcirculation group ( $89.1\pm 5.5\%$ ) compared to the impaired microcirculation group ( $71.4\pm 15.9\%$ ), with a highly significant difference ( $p<0.001$ ). These findings suggest that preserved microcirculation is associated with improved

|                                       | Overall        | Preserved microcirculation | Impaired microcirculation | <i>p</i> -value |
|---------------------------------------|----------------|----------------------------|---------------------------|-----------------|
| Male gender                           | 21 (48%)       | 7 (29%)                    | 14 (70%)                  | <b>0.007</b>    |
| Age [years]                           | 84.28 ± 3.85   | 84.70 ± 0.89               | 83.68 ± 0.84              | 0.476           |
| Body temperature [°C]                 | 35.75 ± 1.51   | 35.92 ± 1.24               | 35.54 ± 1.79              | 0.353           |
| Respiratory rate [/Minute]            | 18.23 ± 6.10   | 17.79 ± 5.70               | 18.70 ± 6.60              | 0.731           |
| Mean arterial pressure [mmHg]         | 70.06 ± 13.84  | 71.42 ± 13.82              | 67.25 ± 14.43             | 0.337           |
| Systolic arterial pressure [mmHg]     | 108.38 ± 21.97 | 109.21 ± 18.43             | 105.00 ± 25.28            | 0.540           |
| Diastolic arterial pressure [mmHg]    | 51.49 ± 12.85  | 53.08 ± 12.82              | 49.65 ± 13.48             | 0.395           |
| Heart rate [/Minute]                  | 86.47 ± 23.06  | 84.63 ± 20.88              | 89.95 ± 25.84             | 0.463           |
| SOFA on admission                     | 9.33 ± 3.66    | 9.64 ± 3.39                | 9.38 ± 3.74               | 0.826           |
| Body mass index                       | 25.80 ± 4.32   | 26.30 ± 0.82               | 25.35 ± 1.21              | 0.556           |
| Norepinephrine [µg/kg/minute]         | 0.30 ± 0.28    | 0.27 ± 0.22                | 0.34 ± 0.34               | 0.404           |
| Cause of shock                        |                |                            |                           | 0.594           |
| Sepsis                                | 9 (19%)        | 4 (17%)                    | 5 (25%)                   |                 |
| Cardiogenic                           | 30 (68%)       | 16 (67%)                   | 14 (70%)                  |                 |
| Neurological                          | 1 (2%)         | 1 (4%)                     | 0 (0%)                    |                 |
| Haemorrhagic                          | 4 (9%)         | 3 (13%)                    | 1 (5%)                    |                 |
| Comorbidities                         |                |                            |                           |                 |
| Heart failure                         | 12 (26%)       | 8 (33%)                    | 4 (20%)                   | 0.323           |
| Chronic kidney disease                | 16 (34%)       | 11 (46%)                   | 5 (25%)                   | 0.153           |
| Any Malignancy                        | 6 (13%)        | 2 (8%)                     | 4 (20%)                   | 0.261           |
| Diabetes mellitus                     | 16 (34%)       | 7 (29%)                    | 9 (45%)                   | 0.277           |
| Chronic obstructive pulmonary disease | 9 (19%)        | 5 (21%)                    | 4 (20%)                   | 0.946           |
| Liver cirrhosis                       | 1 (2%)         | 1 (4%)                     | 0 (0%)                    | 1.000           |
| Smoking history                       | 7 (16%)        | 3 (15%)                    | 4 (31%)                   | 0.279           |
| Arterial hypertension                 | 29 (66%)       | 15 (63%)                   | 14 (70%)                  | 0.601           |

**Table 1.** Baseline characteristics on ICU admission. Significant values are in [bold].

|   | Preserved microcirculation | Impaired microcirculation | <i>p</i> -value   |
|---|----------------------------|---------------------------|-------------------|
| Capillary refill time [sec]                 | 3.43 ± 0.43                | 4.11 ± 0.40               | 0.185             |
| Lactate on admission [mmol/L]               | 6.18 ± 0.87                | 5.93 ± 0.88               | 0.850             |
| SDF measurement at baseline measurement     |                            |                           |                   |
| Number of crossings (n/mm)                  | 51.50 ± 11.27              | 47.38 ± 11.82             | 0.247             |
| De-Backer-density (n/mm)                    | 10.95 ± 2.40               | 10.12 ± 2.47              | 0.268             |
| Number of crossings (small) (n/mm)          | 20.83 ± 11.74              | 26.94 ± 11.76             | 0.094             |
| De-Backer-density (small) (n/mm)            | 4.43 ± 2.50                | 5.69 ± 2.51               | 0.103             |
| Perfused number of crossings (n/mm)         | 48.22 ± 11.10              | 39.21 ± 14.05             | <b>0.026</b>      |
| Perfused De-Backer-density (n/mm)           | 10.25 ± 2.36               | 8.33 ± 3.00               | <b>0.026</b>      |
| Perfused number of crossings (small) (n/mm) | 18.16 ± 10.13              | 19.26 ± 10.16             | 0.721             |
| Perfused De-Backer-density (small) (n/mm)   | 3.86 ± 2.15                | 4.11 ± 2.18               | 0.708             |
| Percentage of perfused vessels [%]          | 92.94 ± 4.18               | 87.39 ± 4.18              | <b>0.014</b>      |
| Percentage of perfused small vessels [%]    | 89.12 ± 5.50               | 71.42 ± 15.94             | <b>&lt; 0.001</b> |

**Table 2.** Microcirculatory values on ICU-admission including the SDF-measurement. Significant values are in [bold].

perfusion in overall and small vessels compared to impaired microcirculation. Notably, no adverse events that could be related to the SDF measurement were reported in either group.

### Serum lactate values and kinetics

The maximum lactate value during the first 24 h after ICU admission was higher in the impaired microcirculation group (9.9 mmol/L ± 6.3 compared to 7.3 mmol/L ± 5.7). However, the difference did not reach statistical significance ( $p=0.084$ ). Similarly, in the case of the maximum lactate value during the first 48 h, patients with an impaired microcirculation exhibited a higher, but statistically not significantly different, mean level at 10.2 mmol/L ± 6.1 compared to those with a preserved microcirculation (7.3 mmol/L ± 5.7,  $p=0.059$ ). Regarding lactate kinetics, Delta6h, there was no difference. The impaired microcirculation group had a mean

|   | Preserved microcirculation | Impaired microcirculation | p-value      |
|---|----------------------------|---------------------------|--------------|
| ICU-Treatment                               |                            |                           |              |
| Renal replacement therapy                   | 8% (2)                     | 35% (7)                   | <b>0.029</b> |
| Mechanical ventilation                      | 71% (17)                   | 75% (15)                  | 0.757        |
| Extracorporeal life support                 | 8% (2)                     | 0% (0)                    | 0.186        |
| Limitation of life sustaining therapy (LST) |                            |                           |              |
| Therapy withdrawn                           | 19% (4)                    | 26% (9)                   | 0.583        |
| Therapy withheld                            | 57% (12)                   | 53% (10)                  | 0.775        |
| Any limitation of LST                       | 79% (19)                   | 80% (16)                  | 0.946        |
| Day of any limitation of LST                | 8.01 ( $\pm 22.47$ )       | 1.38 ( $\pm 1.78$ )       | 0.123        |

**Table 3.** ICU-treatment and treatment limitations. Significant values are in [bold].

|                                   | Preserved microcirculation | Impaired microcirculation | p            |
|-----------------------------------|----------------------------|---------------------------|--------------|
| Length of stay on ICU [days]      | 7.34 ( $\pm 8.90$ )        | 2.60 ( $\pm 3.21$ )       | <b>0.015</b> |
| Length of stay in hospital [days] | 16.26 ( $\pm 20.92$ )      | 5.30 ( $\pm 9.73$ )       | <b>0.019</b> |
| 30-days mortality                 | 63% (15)                   | 90% (18)                  | <b>0.036</b> |
| 6-months mortality                | 75% (18)                   | 90% (17)                  | 0.226        |

**Table 4.** Short- and long-term outcome. Significant values are in [bold].


of 2.6 mmol/L  $\pm 3.3$ , while the preserved microcirculation group had a mean of 2.0 mmol/L  $\pm 2.6$ . The p-value for this comparison was 0.256, indicating no significant difference. Lastly, Delta24h values showed a mean reduction of 5.2 mmol/L  $\pm 3.7$  for the impaired microcirculation group and 4.2 mmol/L  $\pm 3.7$  for the preserved microcirculation group. Again, the difference was not statistically significant ( $p=0.177$ ).

### Intensive care treatment and treatment limitations

Numerous differences were observed in the application of ICU-specific interventions (see Table 3). Concerning Renal Replacement Therapy (RRT), the impaired microcirculation group exhibited a markedly higher utilisation rate at 35%, in contrast to the preserved microcirculation group at 8% ( $p=0.029$ ). Conversely, no significant variance emerged for mechanical ventilation between the two groups, with 71% of cases in the preserved microcirculation group and 75% in the impaired microcirculation group ( $p=0.757$ ). Extracorporeal Life Support (ECLS) displayed a trend, though statistically insignificant, toward reduced incidence in the impaired microcirculation group (0.0%) compared to the preserved microcirculation group (8%), yielding a p-value of 0.186. In the context of life-sustaining therapy (LST) limitations, several parameters were compared between the impaired microcirculation and preserved microcirculation groups. Concerning the withdrawal of therapy, a higher proportion was observed in the impaired microcirculation group at 26% (9 cases), compared to 19% (4 cases) in the preserved microcirculation group, although this difference did not reach statistical significance ( $p=0.583$ ). However, the withholding of therapy occurred almost equally in the impaired microcirculation group at 53% (10 cases), and in the preserved microcirculation group (57% (12 cases)), with no significant difference noted ( $p=0.775$ ). The overall incidence of any limitation on life-sustaining therapy (LST) demonstrated a comparable occurrence between the impaired microcirculation group (80% or 16 cases) and the preserved microcirculation group (79% or 19 cases), with a non-significant p-value of 0.946. Examining the timing of any limitation on LST, the impaired microcirculation group experienced limitations significantly earlier after ICU admission (1.4 days  $\pm 1.8$ ) compared to the preserved microcirculation group (8.0 days  $\pm 22.5$ ), although this difference did not attain statistical significance ( $p=0.123$ ).

### Primary outcome

Significant differences were observed in patient outcomes between the impaired microcirculation and preserved microcirculation groups (see Table 4). Notably, the length of stay in the ICU was substantially shorter for the impaired microcirculation group (2.6 days  $\pm 3.2$ ) compared to the preserved microcirculation group (7.3 days  $\pm 8.9$ ), with a statistically significant p-value of 0.015. Similarly, the length of hospital stay displayed a significant disparity, with the impaired microcirculation group exhibiting a mean stay of 5.3 days ( $\pm 9.7$ ), as opposed to 16.3 days ( $\pm 20.9$ ) for the preserved microcirculation group ( $p=0.019$ ). Examining mortality outcomes, the 30-day mortality rate was notably higher in the impaired microcirculation group, with 90% (18 cases) compared to 63% (15 cases) in the preserved microcirculation group ( $p=0.036$ ). In the Cox regression analysis, HR for patients suffering from an impaired microcirculation was 2.52 (95.0% confidence interval 1.18 to 5.41,  $p=0.018$ , Fig. 2). The association remained significant after adjusting for age, gender and SOFA on admission (adjusted HR 3.245 (95% CI 1.178 to 8.943,  $p=0.023$ ). ICU survivors evidenced a longer length of stay without reaching statistical significance (7.2  $\pm 7.3$  days versus 3.9  $\pm 6.8$  days,  $p=0.078$ ). Sublingual microcirculatory values did not differ 24 h after ICU admission (see supplemental Table 1).



**Fig. 2.** Kaplan-Meier for 30-days probability of survival after ICU-admission with 95% CI. Blue line: Preserved microcirculation; Orange line: Impaired microcirculation.  $p=0.023$  (cox-regression analysis).

### 6 Months follow-up

The 6-month mortality rate, while higher in the impaired microcirculation group at 90% (17 cases) compared to 75% (18 cases) in the preserved microcirculation group, did not reach statistical significance ( $p=0.226$ ).

### Discussion

The present study was the first to evaluate the microcirculation in a highly vulnerable group of old patients suffering from shock. Patients with an impaired microcirculation on admission to the ICU had a significantly shorter ICU and hospital stay and a significantly higher 30-day mortality, reaching 90% at three months. Almost a quarter of a century ago, De Backer et al.<sup>16</sup> described critical chances of the sublingual microcirculation in septic and cardiogenic shock<sup>44,45</sup>. In 2020, Bruno et al.<sup>21</sup> evaluated SDF-measurement as both safe and feasible in 13 older patients suffering from dehydration, but not in shock. In this study, dehydration was associated with a significantly lower percentage of perfused small vessels compared to control ( $83.1 \pm 7.7\%$  versus  $88.0 \pm 6.0\%$ ,  $P < 0.05$ ).

Currently, the most common method of assessing the microcirculation is the measurement of serum lactate and its kinetics. We know from a previous retrospective analysis that both values are associated with the ICU outcome. For example, Bruno et al., included 3299 septic patients, and found that 46% exhibited  $\leq 0\%$  lactate clearance, and 54% had  $> 0\%$  clearance after 6 h. Multilevel logistic regression models were used to examine their impact on intensive care unit (ICU) mortality. Results showed that patients with lactate clearance  $> 0\%$  had lower sepsis-related organ failure assessment scores and creatinine levels. ICU mortality was significantly lower in this group (14% versus 32%) and remained significant after adjustment (aOR 0.43 95% CI 0.36–0.53;  $p < 0.001$ )<sup>40</sup>. Similarly, in a subgroup analysis of the COVIP study, a prospective international observation study of patients aged 70 years or older admitted to an ICU due to Covid-19, we analysed 2860 patients. Patients with an elevated baseline serum lactate had a significantly higher ICU- and 3-month mortality (53% vs. 43%, and 71% vs. 57%, respectively;  $p < 0.001$ ). The maximum lactate concentration on day 1 independently predicted ICU, 30-day, and 3-month mortality after adjustment. In patients with baseline lactate  $\geq 2$  mmol/L, decreasing lactate concentration over time was inversely associated with ICU mortality after multivariate adjustment<sup>43</sup>. Our

present study showed slightly higher lactate levels in patients with impaired microcirculation without reaching statistical significance.

In everyday clinical practice, shock resuscitation focuses primarily on normalising serum lactate levels and mean arterial pressure (MAP) with fluids and vasopressors<sup>46,47</sup>. However, there is a constant risk of fluid overload in shock<sup>48</sup> and it is crucial to recognise that achieving a normal MAP does not guarantee an improvement in microcirculatory flow and tissue perfusion, especially in cases where there is a divergence between macro- and microcirculation<sup>5</sup>. Indeed, in a study of 49 patients, Sakr et al.<sup>49</sup> demonstrated that those with impaired microcirculation had a significantly worse outcome despite the normalisation of macrohaemodynamic values. Conversely, persistent hyperlactatemia is not always a direct indication of tissue hypoperfusion and should be approached with caution<sup>50</sup>. While high blood lactate levels are correlated with an increased risk of mortality<sup>51,52</sup>, relying on blood lactate alone as a resuscitation target may heighten the risk of “over-resuscitation” and potentially lead to harm<sup>53,54</sup>. In fact, real-time microcirculation measurement has repeatedly been proposed as a relevant clinical tool to assist in titrating fluids and vasopressors more precisely<sup>55,56</sup>. Capillary refill time and serum lactate are established parameters in septic and cardiogenic shock<sup>6,57</sup>. However, the recently published DAMIS trial did not find any benefits for survival using SDF measurement to guide therapy in patients suffering from shock<sup>27</sup>.

By contrast to the microSOAP and DAMIS trials, the present study found that microcirculatory values were significantly associated with outcome. The microSOAP trial ( $n=501$  ICU patients) examined a mixed ICU population and found a significant independent association between lactate levels and several macrohaemodynamic variables with hospital mortality but not microcirculatory variables<sup>33</sup>. On the other hand, the results are in line with the smaller MicroDAIMON study ( $n=97$  ICU patients), which showed an independent association between baseline MFI  $<2.6$  and the outcome (OR 4.59 95% CI 1.34–15.75,  $p=0.015$ )<sup>58</sup>.

However, the aforementioned DAMIS study did not find a significant association between the sPPV on admission and the short-term outcomes. As in the present study, all patients in DAMIS underwent prompt haemodynamic stabilisation before the initial Sidestream Dark Field (SDF) measurement. This circumstance could account for the relatively elevated values of sPPV and the absence of a discernible association between sPPV and the primary study outcome. Microvascular abnormalities exhibit variations across distinct types of shock. Notably, septic shock is characterised by a distinctive microvascular inhomogeneous flow<sup>59</sup>, whereas patients experiencing cardiogenic shock may encounter a reduction in vascular density, with acknowledged heterogeneity also present in cardiogenic shock. Typically, flow-related variables are recommended for risk stratification and management adjustments in fluid therapy rather than those representing capillary density<sup>60</sup>. The microvascular flow index (MFI) is a frequently used flow variable, and an abnormal and low MFI (defined as  $<2.6$ ), particularly on the first day of ICU admission, is associated with adverse outcomes<sup>58</sup>. It's worth noting that MFI necessitates manual interpretation by the investigator, whereas AVA 4.3 C does not offer information about the microcirculatory flow pattern. Alternative approaches, such as the POEM score, emphasise the flow pattern significantly<sup>61</sup>. The study protocol we used for this trial intentionally excluded subjective assessment of the flow pattern by the investigator, as the software lacks the capability to automatically calculate this parameter. The use of an automatic algorithm surpasses individual (subjective) evaluation by providing independent information about microvascular perfusion (yes/no), density, and the percentage of perfused vessels. Earlier studies have identified a satisfactory correlation between a low proportion of perfused vessels (PPV) and low MFI, with a PPV of 88% in the low MFI group and a PPV of 94% in the high MFI group<sup>60</sup>. Furthermore, PPV demonstrates low observer variability<sup>62</sup>.

Notably, the mortality rates from the present study were higher than we expected from the previous studies. However, depending on its aetiology, shock is associated with mortality rates between 30 and 90%<sup>63</sup>. Recently, we used data from the eICU Collaborative Research Database (9,385 patients) to perform a multilevel logistic regression analysis to compare mortality, organ support rates, and length of stay between old (65–79 years) and very old (80 years and older) intensive care patients with sepsis and septic shock. In patients with septic shock, very old patients also showed slightly higher mortality than old patients (38 vs. 36%; aOR 1.50, 95% CI 1.10–2.06;  $p=0.01$ )<sup>42</sup>. In another analysis, octogenarians and nonagenarians who were admitted to an ICU showed a mortality of 40 and 45%, respectively after 30 days from ICU admission<sup>9</sup>. Especially old patients who are admitted to an ICU with a higher degree of frailty evidence a significantly higher mortality<sup>12,64</sup>. In VIP-2, there was a relevant difference between ICU- and 30-days mortality (31% versus 42%)<sup>65</sup>.

These associations were independent of the limitations of LST. This is of considerable interest because we know from retrospective studies that any restriction of life-sustaining therapy is associated with significantly increased 30-day mortality and length of stay<sup>66</sup>. Bruno et al.<sup>67</sup> evaluated 415 acutely admitted ICU patients aged 80 years or more. In this analysis, patients with any limitation of LST had a significantly longer length of stay (144 [IQR 72–293] versus 96 [IQR 47.25–231.5] hours,  $p=0.026$ ) and an increased 30-day mortality (86% versus 16%,  $p<0.001$ ).

The present study paves the way for a more in-depth analysis of the implications of real-time microcirculatory assessment in shock resuscitation. Future research efforts should focus on identifying optimal therapeutic interventions tailored to specific patterns of microcirculatory derangement and their relationship with patient-centred outcomes in very old intensive care patients suffering from shock. The VIPPER study clearly underlined that the percentage of perfused small vessels is an early independent indicator for short-term mortality, but to date, without clinical evidence from randomized-controlled trials showing a survival benefit in measuring the sublingual microcirculation, there is no role for routine assessment. To achieve valid data, we need, firstly, to employ technical devices with shorter software processing times and improved video quality. Secondly, larger retrospective analyses are required to generate comprehensive data. Thirdly, we need better data from basic research to determine which parameters should be addressed and how. These findings are necessary for conducting randomized-controlled trials.

## Limitations

Several limitations of this study warrant acknowledgment. Initially, sublingual microcirculation was assessed only at two specific time points. Nonetheless, prior research has demonstrated that evaluating sublingual microcirculation on the first day of ICU admission provides valuable prognostic insights, while subsequent measurements yield limited prognostic information<sup>58</sup>. Conducting measurements upon admission allows for a direct assessment of microcirculation immediately post-resuscitation, revealing potential haemodynamic inconsistencies. Although a minority of videos exhibited lower technical quality, potentially impacting the generalisability of microcirculatory data, it is essential to note that the quality scores obtained align with those reported in other studies<sup>25,68</sup>. Moreover, all videos were conducted by experienced and trained investigators. Additionally, the SDF assessment primarily focused on sPPV, which is considered the most promising and reproducible indicator reflecting a patient's microcirculatory tissue perfusion. While density values may also be significant, cut-off values are less defined in the literature, and density parameters are predominantly utilised within individuals rather than across individuals. It is crucial to highlight that no established standard approach for optimising microcirculation exists. Furthermore, a considerable percentage of patients exhibited varying degrees of life-sustaining therapy limitations. In 80% of the patients, life-sustaining therapy was either withheld, or withdrawn or both. This is recognised as a notable confounder for short-term mortality in critically ill patients<sup>69</sup>. Lastly, as pointed out by Ospina-Tascón et al.<sup>70</sup>, selecting mortality as the primary endpoint in an intensive care setting may not be the optimal strategy for assessing the value of tools for outcome prediction, especially in studies with smaller number of patients.

## Conclusion

Measuring sublingual microcirculation in critically ill old patients in shock on ICU admission is safe, feasible, and provides additional independent prognostic information about the outcome.

## Data availability

The anonymised data can be requested from the authors (Dr. Raphael R. Bruno, Raphael.bruno@med.uni-duesseldorf.de) if required.

Received: 3 June 2024; Accepted: 22 October 2024

Published online: 27 October 2024

## References

- Standl, T. et al. The nomenclature, definition and distinction of types of shock. *Dtsch. Arztebl Int.* **115**(45), 757–768 (2018).
- Dilken, O., Ergin, B. & Ince, C. Assessment of sublingual microcirculation in critically ill patients: consensus and debate. *Ann. Transl. Med.* **8**(12), 793 (2020).
- Güven, G., Hilty, M. P. & Ince, C. Microcirculation physiology, pathophysiology, and clinical application. *Blood Purif.* **49**(1–2), 143–150 (2020).
- Jung, C. & Kelm, M. Evaluation of the microcirculation in critically ill patients. *Clin. Hemorheol. Microcirc.* **61**(2), 213–224 (2015).
- Arnold, R. C. et al. Discordance between microcirculatory alterations and arterial pressure in patients with hemodynamic instability. *J. Crit. Care* **27**(5), 531e1–531e7 (2012).
- Hernandez, G. et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. *JAMA* **321**(7), 654–664 (2019).
- Ait-Oufella, H. et al. Mottling score predicts survival in septic shock. *Intensive Care Med.* **37**(5), 801–807 (2011).
- Bakker, J. et al. Current practice and evolving concepts in septic shock resuscitation. *Intensive Care Med.* **48**(2), 148–163 (2021).
- Bruno, R. R. et al. Management and outcomes in critically ill nonagenarian versus octogenarian patients. *BMC Geriatr.* **21**(1), 576 (2021).
- de Lange, D. W. et al. Cumulative prognostic score predicting mortality in patients older than 80 years admitted to the ICU. *J. Am. Geriatr. Soc.* (2019).
- Guidet, B. et al. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study. *Intensive Care Med.* **46**(1), 57–69 (2020).
- Wernly, B. et al. Frailty's influence on 30-day mortality in old critically ill ICU patients: a bayesian analysis evaluating the clinical frailty scale. *Ann. Intensive Care.* **13**(1), 126 (2023).
- Flaatten, H. et al. The status of intensive care medicine research and a future agenda for very old patients in the ICU. *Intensive Care Med.* **43**(9), 1319–1328 (2017).
- Leblanc, G., Boumendil, A. & Guidet, B. Ten things to know about critically ill elderly patients. *Intensive Care Med.* **43**(2), 217–219 (2017).
- Ihra, G. C. et al. Development of demographics and outcome of very old critically ill patients admitted to intensive care units. *Intensive Care Med.* **38**(4), 620–626 (2012).
- De Backer, D., Creteur, J., Preiser, J. C., Dubois, M. J. & Vincent, J. L. Microvascular blood flow is altered in patients with sepsis. *Am. J. Respir. Crit. Care Med.* **166**(1), 98–104 (2002).
- Spronk, P. E., Zandstra, D. F. & Ince, C. Bench-to-bedside review: sepsis is a disease of the microcirculation. *Crit. Care* **8**(6), 462–468 (2004).
- Massey, M. J. et al. Microcirculatory perfusion disturbances in septic shock: results from the ProCESS trial. *Crit. Care* **22**(1), 308 (2018).
- Ince, C. The microcirculation is the motor of sepsis. *Crit. Care* **9**(Suppl 4), S13–S19 (2005).
- Jung, C. et al. Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy. *Clin. Res. Cardiol.* **104**(8), 679–687 (2015).
- Bruno, R. R. et al. Sublingual microcirculation detects impaired perfusion in dehydrated older patients. *Clin. Hemorheol. Microcirc.* (2020).
- Verdant, C. L. et al. Evaluation of sublingual and gut mucosal microcirculation in sepsis: a quantitative analysis. *Crit. Care Med.* **37**(11), 2875–2881 (2009).
- Qian, J. et al. Post-resuscitation intestinal microcirculation: its relationship with sublingual microcirculation and the severity of post-resuscitation syndrome. *Resuscitation* **85**(6), 833–839 (2014).
- Bruno, R. R., Schemmelmann, M., Wollborn, J., Kelm, M. & Jung, C. Evaluation of a shorter algorithm in an automated analysis of sublingual microcirculation. *Clin. Hemorheol. Microcirc.* **76**(2), 287–297 (2020).

25. Bruno, R. R. et al. Direct assessment of microcirculation in shock: a randomized-controlled multicenter study. *Intensive Care Med.* **49**(6), 645–655 (2023).
26. Bruno, R. R. et al. A microcirculation-guided trial: never trying is worse than failing. *Intensive Care Med.* **49**(12), 1555–1556 (2023).
27. Bruno, R. R., Hernandez, G., Wollborn, J., Saugel, B. & Jung, C. Of the Dsg. Microcirculation information in clinical decision making: Rome wasn't built in a day. *Intensive Care Med.* **49**(10), 1272–1273 (2023).
28. Kanoore Edul, V. S. & Dubin, A. Pitfalls in the use of microcirculation as a resuscitation goal. *Intensive Care Med.* **49**(10), 1268–1269 (2023).
29. Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* **315**(8), 801–810 (2016).
30. Bruno, R. R. et al. Sublingual microcirculation in prehospital critical care medicine: a proof-of-concept study. *Microcirculation* **27**(5), e12614 (2020).
31. Massey, M. J. et al. The microcirculation image quality score: development and preliminary evaluation of a proposed approach to grading quality of image acquisition for bedside videomicroscopy. *J. Crit. Care* **28**(6), 913–917 (2013).
32. De Backer, D. et al. How to evaluate the microcirculation: report of a round table conference. *Crit. Care* **11**(5), R101 (2007).
33. Vellinga, N. A. et al. International study on microcirculatory shock occurrence in acutely ill patients. *Crit. Care Med.* **43**(1), 48–56 (2015).
34. Spanos, A., Jhanji, S., Vivian-Smith, A., Harris, T. & Pearse, R. M. Early microvascular changes in sepsis and severe sepsis. *Shock* **33**(4), 387–391 (2010).
35. Kanoore Edul, V. S. et al. The effects of arterial hypertension and age on the Sublingual Microcirculation of healthy volunteers and outpatients with Cardiovascular Risk factors. *Microcirculation* **22**(6), 485–492 (2015).
36. Donadello, K. et al. Sublingual and muscular microcirculatory alterations after cardiac arrest: a pilot study. *Resuscitation* **82**(6), 690–695 (2011).
37. Pranskunas, A. et al. Effects of whole body heat stress on sublingual microcirculation in healthy humans. *Eur. J. Appl. Physiol.* **115**(1), 157–165 (2015).
38. Favory, R., Salgado, D., Vincent, J. L. & De Backer, D. Can normal be more normal than normal? *Crit. Care Med.* **38**(2), 737–738 (2010).
39. Guidet, B. et al. Withholding or withdrawing of life-sustaining therapy in older adults ( $\geq 80$  years) admitted to the intensive care unit. *Intensive Care Med.* **44**(7), 1027–1038 (2018).
40. Bruno, R. R. et al. Failure of Lactate Clearance predicts the outcome of critically ill septic patients. *Diagn. (Basel)* **10**, 12 (2020).
41. Jung, C. et al. Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. *Crit. Care* **25**(1), 344 (2021).
42. Bruno, R. R. et al. ICU-Mortality in old and very old patients suffering from Sepsis and septic shock. *Front. Med. (Lausanne)* **8**, 697884 (2021).
43. Bruno, R. R. et al. Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients. *Ann. Intensive Care* **11**(1), 128 (2021).
44. De Backer, D., Creteur, J., Dubois, M. J., Sakr, Y. & Vincent, J. L. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. *Am. Heart J.* **147**(1), 91–99 (2004).
45. Merdji, H. et al. Microcirculatory dysfunction in cardiogenic shock. *Ann. Intensive Care* **13**(1), 38 (2023).
46. Evans, L. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* **47**(11), 1181–1247 (2021).
47. Marik, P. E., Monnet, X. & Teboul, J. L. Hemodynamic parameters to guide fluid therapy. *Ann. Intensive Care* **1**(1), 1 (2011).
48. Malbrain, M. et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy. *Ann. Intensive Care* **8**(1), 66 (2018).
49. Sakr, Y., Dubois, M. J., De Backer, D., Creteur, J. & Vincent, J. L. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. *Crit. Care Med.* **32**(9), 1825–1831 (2004).
50. Gutierrez, G. & Williams, J. D. The riddle of hyperlactatemia. *Crit. Care* **13**(4), 176 (2009).
51. Casserly, B. et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the surviving Sepsis Campaign database. *Crit. Care Med.* **43**(3), 567–573 (2015).
52. Nichol, A. et al. Dynamic lactate indices as predictors of outcome in critically ill patients. *Crit. Care* **15**(5), R242 (2011).
53. Vincent, J. L., Quintairos, E. S. A., Couto, L. Jr. & Taccone, F. S. The value of blood lactate kinetics in critically ill patients: a systematic review. *Crit. Care* **20**(1), 257 (2016).
54. Levy, B. Lactate and shock state: the metabolic view. *Curr. Opin. Crit. Care* **12**(4), 315–321 (2006).
55. Thooft, A. et al. Effects of changes in arterial pressure on organ perfusion during septic shock. *Crit. Care* **15**(5), R222 (2011).
56. Marik, P. E. & Weinmann, M. Optimizing fluid therapy in shock. *Curr. Opin. Crit. Care* **25**(3), 246–251 (2019).
57. Merdji, H. et al. Performance of early Capillary Refill Time Measurement on outcomes in cardiogenic shock: an observational, prospective multicentric study. *Am. J. Respir. Crit. Care Med.* **206**(10), 1230–1238 (2022).
58. Scorcella, C. et al. MicroDAIMON study: Microcirculatory DAILY MONitoring in critically ill patients: a prospective observational study. *Ann. Intensive Care* **8**(1), 64 (2018).
59. Boerma, E. C., Mathura, K. R., van der Voort, P. H., Spronk, P. E. & Ince, C. Quantifying bedside-derived imaging of microcirculatory abnormalities in septic patients: a prospective validation study. *Crit. Care* **9**(6), R601–R606 (2005).
60. Pranskunas, A., Koopmans, M., Koetsier, P. M., Pilvinis, V. & Boerma, E. C. Microcirculatory blood flow as a tool to select ICU patients eligible for fluid therapy. *Intensive Care Med.* **39**(4), 612–619 (2013).
61. Naumann, D. N. et al. Real-time point of care microcirculatory assessment of shock: design, rationale and application of the point of care microcirculation (POEM) tool. *Crit. Care* **20**(1), 310 (2016).
62. Hubble, S. M., Kyte, H. L., Gooding, K. & Shore, A. C. Variability in sublingual microvessel density and flow measurements in healthy volunteers. *Microcirculation* **16**(2), 183–191 (2009).
63. Bruno, R. R., Wolff, G., Kelm, M. & Jung, C. Pharmacological treatment of cardiogenic shock—a state of the art review. *Pharmacol. Ther.* **240**, 108230 (2022).
64. Bruno, R. R. et al. The clinical Frailty Scale for mortality prediction of old acutely admitted intensive care patients: a meta-analysis of individual patient-level data. *Ann. Intensive Care* **13**(1), 37 (2023).
65. de Lange, D. W. et al. The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years. *Ann. Intensive Care* **14**(1), 46 (2024).
66. Beil, M. et al. Limiting life-sustaining treatment for very old ICU patients: cultural challenges and diverse practices. *Ann. Intensive Care* **13**(1), 107 (2023).
67. Bruno, R. R. et al. Therapy limitation in octogenarians in German intensive care units is associated with a longer length of stay and increased 30 days mortality: a prospective multicenter study. *J. Crit. Care* **60**, 58–63 (2020).
68. Damiani, E. et al. Impact of microcirculatory video quality on the evaluation of sublingual microcirculation in critically ill patients. *J. Clin. Monit. Comput.* **31**(5), 981–988 (2017).
69. Flaatten, H. et al. The importance of revealing data on limitation of life sustaining therapy in critical ill elderly Covid-19 patients. *J. Crit. Care* **67**, 147–148 (2022).
70. Ospina-Tascon, G. A., Buchele, G. L. & Vincent, J. L. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? *Crit. Care Med.* **36**(4), 1311–1322 (2008).

### Author contributions

RRB analysed the data and wrote the first draft of the manuscript. MS and JH and HM and FD and LP and RM and AS contributed data and contributed to statistical analysis and improved the paper. BG and SL and HF and WS and MM and DL and SQ and MB and MK gave guidance and improved the paper. CJ contributed to statistical analysis, gave guidance and improved the paper. All authors read and approved the final manuscript.

### Funding

Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Forschungskommission of the Medical Faculty of the Heinrich-Heine-University Düsseldorf No. 2020-21 to RRB for a Clinician Scientist Track. Furthermore, institutional support has been received by the German Research Council (SFB 1116, B06) as well as the State of North Rhine Westphalia (Giga for Health: 5GMedizincampus. NRW, Project number 005-2008-0055 and PROFILNRW-2020-107-A, TP4).

### Competing interests

The authors declare no competing interests.

### Ethics approval and consent to participate

The primary competent ethics committee was the Ethics Committee of the University of Duesseldorf, Germany.

### Consent for publication

The manuscript does not contain any individual person's data in any form.

### Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-024-77357-y>.

**Correspondence** and requests for materials should be addressed to C.J.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024